Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 2/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | CCR3 | P51677 | 2/20 | 0.44 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24043594 | 0.81 | POLB (0.69) | YAP1KMT2APOLBGRIN2BFKBP1A | |
| SCHEMBL13342864 | 0.81 | NPC1 (0.59) | KMT2APOLBGRIN2BGRIN1SIGMAR1 | |
| SCHEMBL19982254 | 0.81 | YAP1 (0.57) | YAP1OPRD1CCR3GRIN2BGRIN1 | |
| SCHEMBL28493357 | 0.80 | YAP1 (0.62) | YAP1CCR2KMT2A | |
| SCHEMBL21359143 | 0.80 | YAP1 (0.62) | YAP1CCR2KMT2A | |
| SCHEMBL19974588 | 0.80 | YAP1 (0.68) | YAP1CCR2POLB | |
| SCHEMBL28501789 | 0.80 | YAP1 (0.59) | YAP1CCR2 | |
| SCHEMBL5743274 | 0.79 | SIGMAR1 (0.59) | KMT2APOLBCCR3SIGMAR1 | |
| SCHEMBL21359132 | 0.79 | POLB (0.52) | YAP1KMT2APOLBOPRD1GRIN2B | |
| SCHEMBL21359119 | 0.79 | YAP1 (0.64) | YAP1CCR2POLBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210363128-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-11-25 | — | — | US | disclosed |
| EP-3765015-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. Lee Moffitt Cancer Center & Research Institute, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-111989100-A | YAP1 inhibitors targeting YAP1 interaction with OCT4 | H·李·莫菲特癌症中心研究有限公司 | 2020-11-24 | — | — | CN | disclosed |
| WO-2019178401-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019178401-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-3512839-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053446-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685725-B2 | YAP1 inhibitors that target the interaction of YAP1 with OCT4 | YAP1, YES1, MYC | YAP1 1/4885CCR2 3571/4885KMT2A 1665/4885 |
| US-20210363128-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, MYC, YES1 | YAP1 1/4885CCR2 3602/4885KMT2A 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.